Affymax, Inc. (NASDAQ:AFFY)

CAPS Rating: 2 out of 5

The Company is a biopharmaceutical company developing novel peptide-based drug candidates to improve the treatment of serious and often life-threatening conditions.

Recs

0
Player Avatar crichton1 (< 20) Submitted: 10/9/2009 5:54:26 PM : Outperform Start Price: $22.79 AFFY Score: -60.46

competitive product to Amgen's EPO on the horizon.

Featured Broker Partners


Advertisement